nach oben

Erschienen in:

02.06.2020 | COVID-19 | Review Zur Zeit gratis

Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms

verfasst von: Paulo Ricardo Criado, Beatrice Martinez Zugaib Abdalla, Isabelle Carvalho de Assis, Cristina van Blarcum de Graaff Mello, Gabriela Cacciolari Caputo, Ingrid Campos Vieira

Erschienen in: Inflammation Research | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

SARS-Cov-2 is a single-stranded RNA virus, a Betacoronavirus, composed of 16 non-structural proteins, with specific roles in replication of coronaviruses. The pathogenesis of COVID-19 is not yet fully understood. The virus and host factors interplay among distinct outcomes of infected patients.

Methods

Using MeSH (Medical Subject Headings) in PubMed, authors searched for articles cotaining information on COVID-19 and the skin.

Results

The pathophysiology of the disease is multifactorial: association with innate immune response, hypercoagulability state, lung tissue damage, neurological and/or gastrointestinal tract involvement, monocytic/macrophage activation syndrome, culminating in exaggerated cytokine secretion, called “cytokine storm”, which leads to worsening and death. These systemic conditions may be associated with cutaneous lesions, that have polymorphic aspects, where at histopathological level show involvement in different skin changes. These lesions may be associated with multisystemic manifestations that could occur due to angiotensin-converting enzyme 2 receptor and transmembrane serine protease action, allowing the pulmonary infection and possibly skin manifestation. Several reports in literature show cutaneous lesions similar to chilblain, urticarial eruptions, diffuse or disseminated erythema, livedo racemosa, blue toe syndrome, retiform purpura, vesicle trunk, purpuric exanthema or exanthema with clinical aspects of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) and others.

Conclusions

This review describes the complexity of Covid-19, pathophysiological and clinical aspects, dermatological finding and other dermatological conditions associated with SARS-CoV-2 infection or COVID-19.

Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr. 2020;87(4):281–6.CrossRefPubMedPubMedCentral

Coronavirus Resource Center of the John Hopkins University. Disposable on https://coronavirus.jhu.edu/map.html, 3.

Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16387.CrossRefPubMedPubMedCentral

Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16472.CrossRefPubMedPubMedCentral

Kamali Aghdam M, Jafari N, Eftekhari K. Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report. Infect Dis (Lond). 2020. https://doi.org/10.1080/23744235.2020.1747634.CrossRef

Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. J Am Acad Dermatol. 2020;82(5):e177. https://doi.org/10.1016/j.jaad.2020.03.036.CrossRefPubMedPubMedCentral

Alramthan A, Aldaraji W. A case of COVID-19 presenting in clinical picture resembling chilblains disease. First report from the Middle East. Clin Exp Dermatol. 2020. https://doi.org/10.1111/ced.14243.CrossRefPubMedPubMedCentral

Zhang Y, Cao W, Xiao M, Li YJ, Yang Y, Zhao J, Zhou X, Jiang W, Zhao YQ, Zhang SY, Li TS. Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia. Zhonghua Xue Ye Xue Za Zhi. 2020;41:E006. https://doi.org/10.3760/cma.j.issn.0253-2727.2020.0006.CrossRefPubMed

Li Taisheng, Hongzhou Lu, Zhang Wenhong. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):687–90. https://doi.org/10.1080/22221751.2020.1741327.CrossRefPubMed

10.

Mazzotta F, Toccoli T. Acute acro-ischemia in the child at the time of COVID-19. Eur J Ped Dermatol. https://www.ejpd.com/en/Mondayscase. Accessed 9 Apr 2020.

11.

Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020. https://doi.org/10.1016/j.trsl.2020.04.007.CrossRefPubMedPubMedCentral

12.

Marzano AV, Genovese G, Fabbrocini G, Pigatto P, Monfrecola G, Piraccini BM, Veraldi S, Rubegni P, Cusini M, Caputo V, Rongioletti F, Berti E, Calzavara-Pinton P. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.04.044.CrossRefPubMedPubMedCentral

13.

Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: transient livedo reticularis. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.04.018.CrossRefPubMedPubMedCentral

14.

Estébanez A, Pérez-Santiago L, Silva E, Guillen-Climent S, García-Vázquez A, Ramón MD. Cutaneous manifestations in COVID-19: a new contribution. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16474.CrossRefPubMedPubMedCentral

15.

Mahé A, Birckel E, Krieger S, Merklen C, Bottlaender L. A distinctive skin rash associated with coronavirus disease 2019? J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16471.CrossRefPubMedPubMedCentral

16.

Jimenez-Cauhe J, Ortega-Quijano D, Prieto-Barrios M, Moreno-Arrones OM, Fernandez-Nieto D. Reply to “COVID-19 can present with a rash and be mistaken for Dengue”: petechial rash in a patient with COVID-19 infection. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.04.016.CrossRefPubMedPubMedCentral

17.

Ehsani AH, Nasimi M, Bigdelo Z. Pityriasis rosea as a cutaneous manifestation of COVID-19 infection. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16579.CrossRefPubMedPubMedCentral

18.

Lu S, Lin J, Zhang Z, Xiao L, Jiang Z, Chen J, Hu C, Luo S. Alert for nonrespiratory symptoms of Coronavirus Disease (COVID-19) patients in epidemic period: a case report of familial cluster with three asymptomatic COVID-19 patients. J Med Virol. 2020. https://doi.org/10.1002/jmv.25776.CrossRefPubMedPubMedCentral

19.

Fernandez-Nieto D, Ortega-Quijano D, Segurado-Miravalles G, Pindado-Ortega C, Prieto-Barrios M, Jimenez-Cauhe J. Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16470.CrossRefPubMedPubMedCentral

20.

Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, Akdis CA, Gao YD. Eleven faces of coronavirus disease 2019. Allergy. 2020. https://doi.org/10.1111/all.14289.CrossRefPubMed

21.

van Damme C, Berlingin E, Saussez S, Accaputo O. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16523.CrossRefPubMedPubMedCentral

22.

Morey-Olivé M, Espiau M, Mercadal-Hally M, Lera-Carballo E, García-Patos V. Cutaneous manifestations in the current pandemic of coronavirus infection disease (COVID 2019). An Pediatr (Engl Ed). 2020. https://doi.org/10.1016/j.anpede.2020.04.002.CrossRef

23.

Paolino G, Canti V, Raffaele Mercuri S, Rovere Querini P, Candiani M, Pasi F. Diffuse cutaneous manifestation in a new mother with COVID-19 (SARS-Cov-2). Int J Dermatol. 2020. https://doi.org/10.1111/ijd.14919.CrossRefPubMedPubMedCentral

24.

Tosti G, Barisani A, Queirolo P, et al. Skin signs resembling vascular acrosyndromes during the COVID-19 outbreak in Italy. Clin Exp Dermatol. 2020. https://doi.org/10.1111/ced.14267.CrossRefPubMedPubMedCentral

25.

Bouaziz JD, Duong T, Jachiet M, et al. Vascular skin symptoms in COVID-19: a French observational study. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16544.CrossRefPubMedPubMedCentral

26.

Amatore F, Macagno N, Mailhe M, et al. SARS-CoV-2 infection presenting as a febrile rash. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16528.CrossRefPubMedPubMedCentral

27.

Diaz-Guimaraens B, Dominguez-Santas M, Suarez-Valle A, et al. Petechial skin rash associated with severe acute respiratory syndrome coronavirus 2 infection. JAMA Dermatol. 2020. https://doi.org/10.1001/jamadermatol.2020.1741.CrossRefPubMed

28.

Tammaro A, Adebanjo GAR, Parisella FR, Pezzuto A, Rello J. Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16530.CrossRefPubMedPubMedCentral

29.

Avellana Moreno R, Villa E, Avellana Moreno V, Estela Villa C, Aparicio M, Fontanella A. Cutaneous manifestation of COVID-19 in images: a case report. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16531.CrossRefPubMedPubMedCentral

30.

Recalcati S, Barbagallo T, Frasin LA, Prestinari F, Cogliardi A, Provero MC, Dainese E, Vanzati A, Fantini F. Acral cutaneous lesions in the time of COVID-19. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16533.CrossRefPubMedPubMedCentral

31.

Zengarini C, Orioni G, Cascavilla A, Horna Solera C, Fulgaro C, Misciali C, Patrizi A, Gaspari V. Histological pattern in Covid-19 induced viral rash. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16569.CrossRefPubMedPubMedCentral

32.

Gianotti R, Veraldi S, Recalcati S, Cusini M, Ghislanzoni M, Boggio F, Fox LP. Cutaneous clinico-pathological findings in three COVID-19-positive patients observed in the metropolitan area of Milan, Italy. Acta Derm Venereol. 2020. https://doi.org/10.2340/00015555-3490.CrossRefPubMed

33.

Ahouach B, Harant S, Ullmer A, Martres P, Bégon E, Blum L, Tess O, Bachmeyer C. Cutaneous lesions in a patient with COVID-19: are they related? Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19168.CrossRefPubMedPubMedCentral

34.

Piccolo V, Neri I, Filippeschi C, Oranges T, Argenziano G, Battarra VC, Berti S, Manunza F, Belloni Fortina A, Di Lernia V, Boccaletti V, De Bernardis G, Brunetti B, Mazzatenta C, Bassi A. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16526.CrossRefPubMedPubMedCentral

35.

Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2002032.CrossRefPubMedPubMedCentral

36.

Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMc2007575.CrossRefPubMedPubMedCentral

37.

Hoehl S, Rabenau H, Berger A, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N Engl J Med. 2020;382(13):1278–80.CrossRefPubMedPubMedCentral

38.

Ma J, Xia P, Zhou Y, et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clin Immunol. 2020;214:108408. https://doi.org/10.1016/j.clim.2020.108408.CrossRefPubMedPubMedCentral

39.

Galván Casas C, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19163.CrossRefPubMedPubMedCentral

40.

Gupta M, Abdelmaksoud A, Jafferany M, Lotti T, Sadoughifar R, Goldust M. COVID-19 and economy. Dermatol Ther. 2020. https://doi.org/10.1111/dth.13329.CrossRefPubMedPubMedCentral

41.

Yan Y, Chen H, Chen L, et al. Consensus of Chinese experts on protection of skin and mucous membrane barrier for health-care workers fighting against coronavirus disease 2019. Dermatol Ther. 2020. https://doi.org/10.1111/dth.13310.CrossRefPubMedPubMedCentral

42.

Elston DM. Occupational skin disease among health care workers during the coronavirus (COVID-19) epidemic. J Am Acad Dermatol. 2020;82(5):1085–6. https://doi.org/10.1016/j.jaad.2020.03.012.CrossRefPubMedPubMedCentral

43.

Tao J, Song Z, Yang L, Huang C, Feng A, Man X. Emergency management for preventing and controlling nosocomial infection of 2019 novel coronavirus: implications for the dermatology department. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19011.CrossRefPubMedPubMedCentral

44.

Jakhar D, Kaur I, Kaul S. Art of performing dermoscopy during the times of coronavirus disease (COVID-19): simple change in approach can save the day! J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16412.CrossRefPubMed

45.

Cavanagh G, Wambier C. Rational hand hygiene during COVID-19 pandemic. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.03.090.CrossRefPubMedPubMedCentral

46.

Chandrasekharan P, Vento M, Trevisanuto D, Partridge E, Underwood MA, Wiedeman J, Katheria A, Lakshminrusimha S. Neonatal resuscitation and post-resuscitation care of infants born to mothers with suspected or confirmed SARS-CoV-2 infection. Am J Perinatol. 2020. https://doi.org/10.1055/s-0040-1709688.CrossRefPubMedPubMedCentral

47.

Der Sarkissian SA, Kim L, Veness M, Yiasemides E, Sebaratnam DF. Recommendations on dermatologic surgery during the COVID-19 pandemic. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.04.034.CrossRef

48.

Rudnicka L, Gupta M, Kassir M, Jafferany M, Lotti T, Sadoughifar R, Goldust M. Priorities for global health community in COVID-19 pandemic. Dermatol Ther. 2020. https://doi.org/10.1111/dth.13361.CrossRefPubMedPubMedCentral

49.

Lan J, Song Z, Miao X, et al. Skin damage among health care workers managing coronavirus disease-2019. J Am Acad Dermatol. 2020;82(5):1215–6. https://doi.org/10.1016/j.jaad.2020.03.014.CrossRefPubMedPubMedCentral

50.

Yu N, Wu L, Su J, Huang K, Zhao S, Chen X. One more paper towel, longer protection. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.03.064.CrossRefPubMedPubMedCentral

51.

Türsen Ü, Türsen B, Lotti T. Coronavirus-days in dermatology. Dermatol Ther. 2020. https://doi.org/10.1111/dth.13438.CrossRefPubMedPubMedCentral

52.

Gupta S, Jangra RS, Gujrathi AV, Mahendra A, Singla R, Sharma A, Gupta S. A novel clinical set up for examining healthy dermatology outpatients in time of Covid-19. Clin Exp Dermatol. 2020. https://doi.org/10.1111/ced.14246.CrossRefPubMedPubMedCentral

53.

Lee SW, Cheong SH, Byun JY, Choi YW, Choi HY. Occupational hand eczema among nursing staffs in Korea: self-reported hand eczema and contact sensitization of hospital nursing staffs. J Dermatol. 2013;40:182–7.CrossRefPubMed

54.

Hamnerius N, Svedman C, Bergendorff O, Bjork J, Bruze M, Ponten A. Wet work exposure and hand eczema among healthcare workers: a cross-sectional study. Br J Dermatol. 2018;178:452–61.CrossRefPubMed

55.

Wollina U. Challenges of COVID-19 pandemic for dermatology. Dermatol Ther. 2020. https://doi.org/10.1111/dth.13430.CrossRefPubMedPubMedCentral

56.

Balato A, Ayala F, Bruze M, et al. European Task Force on Contact Dermatitis statement on coronavirus 19 disease (COVID-19) outbreak and the risk of adverse cutaneous reactions. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.1655.CrossRefPubMed

57.

Lin P, Zhu S, Huang Y, Li L, Tao J, Lei T, Song J, Liu D, Chen L, Shi Y, Jiang S, Liu Q, Xie J, Chen H, Duan Y, Xia Y, Zhou Y, Mei Y, Zhou X, Wu J, Fang M, Meng Z, Li H. Adverse skin reactions among healthcare workers during the coronavirus disease 2019 outbreak: a survey in Wuhan and its surrounding regions. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19089.CrossRefPubMedPubMedCentral

58.

Gheisari M, Araghi F, Moravvej H, Tabary M, Dadkhahfar S. Skin reactions to non-glove personal protective equipment: an emerging issue in the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16492.CrossRefPubMedPubMedCentral

59.

Reinholz M, French LE. Medical education and care in dermatology during the SARS-CoV2 pandemia: challenges and chances. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16391.CrossRefPubMed

60.

McDowell L, Goode S, Sundaresan P. Adapting to a global pandemic through live virtual delivery of a cancer collaborative trial group conference: the TROG 2020 experience. J Med Imaging Radiat Oncol. 2020. https://doi.org/10.1111/1754-9485.13047.CrossRefPubMed

61.

Wollenberg A, et al. European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16411.CrossRefPubMed

62.

Marasca C, Ruggiero A, Fontanella G, Ferrillo M, Fabbrocini G, Villani A. Telemedicine and support groups in order to improve the adherence to treatment and health related quality of life in patients affected by inflammatory skin conditions during COVID-19 emergency. Clin Exp Dermatol. 2020. https://doi.org/10.1111/ced.14245.CrossRefPubMedPubMedCentral

63.

Wang C, Rademaker M, Baker C, Foley P. COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: an Australia/New Zealand consensus statement. Australas J Dermatol. 2020. https://doi.org/10.1111/ajd.13313.CrossRefPubMedPubMedCentral

64.

Rademaker M, Baker C, Foley P, Sullivan J, Wang C. Advice regarding COVID-19 and use of immunomodulators, in patients with severe dermatological diseases. Australas J Dermatol. 2020. https://doi.org/10.1111/ajd.13295.CrossRefPubMedPubMedCentral

65.

Price KN, Frew JW, Hsiao JL, Shi VY. COVID-19 and immunomodulator/immunosuppressant use in dermatology. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.03.046.CrossRefPubMedPubMedCentral

66.

Arora G, Kassir M, Jafferany M, Galadari H, Lotti T, Satolli F, Sadoughifar R, Sitkowska Z, Goldust M. The COVID-19 outbreak and rheumatologic skin diseases. Dermatol Ther. 2020. https://doi.org/10.1111/dth.13357.CrossRefPubMedPubMedCentral

67.

Atzori L, Mugheddu C, Addis G, Sanna S, Satta R, Ferreli C, Atzori MG, Montesu MA, Rongioletti F. Psoriasis health care in the time of the coronavirus pandemic: insights from dedicated centers in Sardinia (Italy). J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16473.CrossRefPubMedPubMedCentral

68.

Ranney ML, Griffeth V, Jha AK. Critical supply shortages—the need for ventilators and personal protective equipment during the Covid-19 Pandemic. N Engl J Med. 2020. https://doi.org/10.1056/NEJMp2006141.CrossRefPubMed

69.

Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediat. 2020. https://doi.org/10.1542/hpeds.2020-0123.CrossRef

70.

Principi N, Rigante D, Esposito S. The role of infection in Kawasaki syndrome. J Infect. 2013;67(1):1–10. https://doi.org/10.1016/j.jinf.2013.04.004.CrossRefPubMedPubMedCentral

71.

Kim GB, Park S, Kwon BS, Han JW, Park YW, Hong YM. Evaluation of the temporal association between Kawasaki disease and viral infections in South Korea. Korean Circ J. 2014;44(4):250–4. https://doi.org/10.4070/kcj.2014.44.4.250.CrossRefPubMedPubMedCentral

72.

Shirato K, Imada Y, Kawase M, Nakagaki K, Matsuyama S, Taguchi F. Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease. J Med Virol. 2014;86(12):2146–53. https://doi.org/10.1002/jmv.23950.CrossRefPubMedPubMedCentral

73.

Chang LY, Lu CY, Shao PL, et al. Viral infections associated with Kawasaki disease. J Formos Med Assoc. 2014;113(3):148–54. https://doi.org/10.1016/j.jfma.2013.12.008.CrossRefPubMedPubMedCentral

74.

Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418–23. https://doi.org/10.1002/jmv.25681.CrossRefPubMedPubMedCentral

75.

Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9. https://doi.org/10.12932/AP-200220-0772.CrossRefPubMed

76.

Crowl JT, Gray EE, Pestal K, Volkman HE, Stetson DB. Intracellular nucleic acid detection in autoimmunity. Annu Rev Immunol. 2017;35:313–36. https://doi.org/10.1146/annurev-immunol-051116-05233.CrossRefPubMedPubMedCentral

77.

Wirestam L, Arve S, Linge P, Bengtsson AA. Neutrophils-important communicators in systemic lupus erythematosus and antiphospholipid syndrome. Front Immunol. 2019;10:2734. https://doi.org/10.3389/fimmu.2019.02734.CrossRefPubMedPubMedCentral

78.

Marzano AV, Ortega-Loayza AG, Heath M, Morse D, Genovese G, Cugno M. Mechanisms of inflammation in neutrophil-mediated skin diseases. Front Immunol. 2019;10:1059. https://doi.org/10.3389/fimmu.2019.01059.CrossRefPubMedPubMedCentral

79.

Martorana D, Bonatti F, Mozzoni P, Vaglio A, Percesepe A. Monogenic autoinflammatory diseases with Mendelian inheritance: genes, mutations, and genotype/phenotype correlations. Front Immunol. 2017;8:344. https://doi.org/10.3389/fimmu.2017.00344.CrossRefPubMedPubMedCentral

80.

Sun NZ, Brezinski EA, Berliner J, Haemel A, Connolly MK, Gensler L, McCalmont TH, Shinkai K. Updates in adult-onset Still disease: atypical cutaneous manifestations and associations with delayed malignancy. J Am Acad Dermatol. 2015;73(2):294–303. https://doi.org/10.1016/j.jaad.2015.04.063.CrossRefPubMed

81.

Criado PR, de Carvalho JF, Ayabe LA, Brandt HR, Romiti R, Maruta CW. Urticaria and dermographism in patients with adult-onset still’s disease. Rheumatol Int. 2012;32(8):2551–5. https://doi.org/10.1007/s00296-011-2025-5.CrossRefPubMed

82.

Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395(10235):1517–20. https://doi.org/10.1016/S0140-6736(20)30920-X.CrossRefPubMedPubMedCentral

83.

Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–32. https://doi.org/10.1002/jmv.25685.CrossRefPubMedPubMedCentral

84.

Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, Mosca M, Bombardieri S. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol. 2020;38(2):175–80.PubMed

85.

Chamseddin B, Marks E, Dominguez A, Wysocki C, Vandergriff T. Refractory macrophage activation syndrome in the setting of adult-onset Still disease with hemophagocytic lymphohistiocytosis detected on skin biopsy treated with canakinumab and tacrolimus. J Cutan Pathol. 2019;46(7):528–31. https://doi.org/10.1111/cup.13466.CrossRefPubMed

86.

Gansner JM, Berliner N. The rheumatology/hematology interface: CAPS and MAS diagnosis and management. Hematology Am Soc Hematol Educ Program. 2018;2018(1):313–7. https://doi.org/10.1182/asheducation-2018.1.313.CrossRefPubMedPubMedCentral

87.

Llamas-Velasco M, Muñoz-Hernández P, Lázaro-González J, et al. Thrombotic occlusive vasculopathy in skin biopsy from a livedoid lesion of a COVID-19 patient. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19222.CrossRefPubMedPubMedCentral

88.

Sarzi-Putting P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, Antinori S, Galli M. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol. 2020;38(2):337–42.

89.

Peterson D, Damsky W, King B. Calm before the storm: understanding the role of JAK inhibitors in COVID-19. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.04.097.CrossRefPubMedPubMedCentral

90.

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–7. https://doi.org/10.1002/path.1570.CrossRefPubMedPubMedCentral

91.

Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8. https://doi.org/10.1016/S0140-6736(20)30937-5.CrossRefPubMedPubMedCentral

92.

Soler MJ, Batlle M, Riera M, Campos B, Ortiz-Perez JT, Anguiano L, Roca-Ho H, Farrero M, Mont L, Pascual J, Perez-Villa F. ACE2 and ACE in acute and chronic rejection after human heart transplantation. Int J Cardiol. 2019;275:59–64. https://doi.org/10.1016/j.ijcard.2018.10.002.CrossRefPubMed

93.

Bjerregaard B, Larsen OB. The Danish pathology register. Scand J Public Health. 2011;39(7 Suppl):72–4.CrossRefPubMed

94.

Shen LW, Mao HJ, Wu YL, Tanaka Y, Zhang W. TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections. Biochimie. 2017;142:1–10. https://doi.org/10.1016/j.biochi.2017.07.016.CrossRefPubMedPubMedCentral

95.

Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: their roles in pathogenesis. J Microbiol Immunol Infect. 2020. https://doi.org/10.1016/j.jmii.2020.03.022.CrossRefPubMedPubMedCentral

96.

Wambier CG, Goren A. SARS-COV-2 infection is likely to be androgen mediated. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.04.032.CrossRefPubMedPubMedCentral

97.

Goren A, Vano-Galvan S, Wambier CG, McCoy J, Gomez-Zubiaur A, Moreno-Arrones OM, Shapiro J, Sinclair R, Gold MH, Kovacevic M, Mesinkovska NA, Goldust M, Washeni K. A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain—a potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol. 2020. https://doi.org/10.1111/jocd.13443.CrossRefPubMedPubMedCentral

98.

Lukassen S, Lorenz Chua R, Trefzer T, Kahn NC, Schneider MA, Muley T, Winter H, Meister M, Veith C, Boots AW, Hennig BP, Kreuter M, Conrad C, Eils R. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020. https://doi.org/10.15252/embj.20105114.CrossRefPubMedPubMedCentral

99.

Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pöhlmann S. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol. 2014;88(2):1293–307. https://doi.org/10.1128/JVI.02202-13.CrossRefPubMedPubMedCentral

100.

Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010;84(24):12658–64. https://doi.org/10.1128/JVI.01542-10.CrossRefPubMedPubMedCentral

101.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020. https://doi.org/10.1016/j.cell.2020.02.052.CrossRefPubMedPubMedCentral

102.

McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020. https://doi.org/10.1016/j.autrev.2020.102537.CrossRefPubMedPubMedCentral

103.

Thachil J. The versatile heparin in COVID-19. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14821.CrossRefPubMedPubMedCentral

104.

Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost. 2020;18(4):786–7. https://doi.org/10.1111/jth.14781.CrossRefPubMedPubMedCentral

105.

Enkhmaa B, Anuurad E, Berglund L. Lipoprotein (a): impact by ethnicity and environmental and medical conditions. J Lipid Res. 2016;57(7):1111–25. https://doi.org/10.1194/jlr.R051904.CrossRefPubMedPubMedCentral

106.

Caforio ALP, Adler Y, Agostini C, Allanore Y, Anastasakis A, et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. Eur Heart J. 2017;38(35):2649–62. https://doi.org/10.1093/eurheartj/ehx321.CrossRefPubMed

107.

Slunga L, Asplund K, Johnson O, Dahlen GH. Lipoprotein (a) in a randomly selected 25–64 year-old population: the Northern Sweden Monica Study. J Clin Epidemiol. 1993;46:617–24.CrossRefPubMed

108.

Nago N, Kayaba K, Hiraoka J, Matsuo H, Goto T, Kario K, Tsutsumi A, Nakamura Y, Igarashi M. Lipoprotein(a) levels in the Japanese population: influence of age and sex, and relation to atherosclerotic risk factors. The Jichi Medical School Cohort Study. Am J Epidemiol. 1995;141(9):815–21. https://doi.org/10.1093/oxfordjournals.aje.a117516.81.CrossRefPubMed

109.

Volpato S, Vigna GB, McDermott MM, Cavalieri M, Maraldi C, Lauretani F, Bandinelli S, Zuliani G, Guralnik JM, Fellin R, Ferrucci L. Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study). Am J Cardiol. 2010;105(12):1825–30. https://doi.org/10.1016/j.amjcard.2010.01.370.CrossRefPubMedPubMedCentral

110.

Muñoz-Torrero JF, Rivas D, Alonso R, Crespo L, Costo A, Roman M, Martín C, Zamorano J. Influence of lipoprotein (a) on inflammatory biomarkers in metabolic syndrome. South Med J. 2012;105(7):339–43. https://doi.org/10.1097/SMJ.0b013e31825b5fb2.CrossRefPubMed

111.

Tang L, Hu Y. Ethnic diversity in the genetics of venous thromboembolism. Thromb Haemost. 2015;114(5):901–9. https://doi.org/10.1160/TH15-04-0330.CrossRefPubMed

112.

Ji HL, Zhao R, Matalon S, Matthay MA. Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility. Physiol Rev. 2020;100(3):1065–75. https://doi.org/10.1152/physrev.00013.2020.CrossRefPubMedPubMedCentral

113.

Wenzhong L, Hualan L. COVID-19: attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv. 2020. https://doi.org/10.26434/chemrxiv.11938173.v7 (Preprint).

Titel: Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms
verfasst von: Paulo Ricardo Criado
Beatrice Martinez Zugaib Abdalla
Isabelle Carvalho de Assis
Cristina van Blarcum de Graaff Mello
Gabriela Cacciolari Caputo
Ingrid Campos Vieira
Publikationsdatum: 02.06.2020
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Inflammation Research / Ausgabe 8/2020
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-020-01370-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms

Abstract

Background

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2020

Fertility and infertility implications in rheumatoid arthritis; state of the art

Inflammasome activation in podocytes: a new mechanism of glomerular diseases

Correction to: Immunoglobulin free light chains: an inflammatory biomarker of diabetes

Thick and yellowish articular effusion: a challenging diagnosis! Focus on cholesterol crystal deposition in joint

Immunoglobulin free light chains: an inflammatory biomarker of diabetes

The protective effects of phoenixin-14 against lipopolysaccharide-induced inflammation and inflammasome activation in astrocytes

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin